NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and has commenced enrollment for a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial by 2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

For more information on NeoStem, click here.

A member of the NeoStem group of companies

As a member of the  NeoStem group of companies, NeoStem Family Stem Cell Banking is uniquely positioned to leverage internal scientific, laboratory,  and clinical expertise to the benefit of its partners and clientele.

NeoStem Family Stem Cell Banking is a wholly-owned subsidiary of Progenitor Cell Therapy, LLC, a NeoStem company (www.progenitorcelltherapy.com). Founded in 1997 by medical and scientific leaders in the cell therapy field, Progenitor Cell Therapy, also known as PCT, has become the leading provider of cell therapy support services to its client companies worldwide from its state-of-the-art clean room facilities and laboratories in the United States.  Headquartered in New Jersey, with operations in California, PCT has performed over 32,000 cell-based procedures since its operations began. An ever-increasing roster of cell therapy companies and leading stem cell transplantation programs rely on PCT.

Each parent choosing NeoStem to collect and store their baby’s cord blood stem cells can share in the same confidence as expressed in PCT by its institutional investors and some of the world’s foremost cell therapy companies which entrust the development of their products to PCT.

Building Collection Partners

In addition to providing cord blood collection and banking services direct to parents, NeoStem also partners with hospitals and physicians to offer a turnkey cord blood banking program that assures the highest quality and ease of use to participating partners.

By partnering with leading hospitals and physicians, NeoStem provides its collection partner programs and stem cell banking clientele with the benefits gained from having a common national infrastructure and shared protocols.

The NeoStem partnership allows participating collection programs to quickly translate the latest cutting-edge scientific and clinical developments into ongoing program improvements focused on ensuring the stem cells collected and stored are of the highest quality and are available for use in the latest therapeutic applications.